Csapo Melinda, Lazar Liviu
Farmimpex Pharmacy Oradea, Romania.
Faculty of Medicine and Pharmacy, University of Oradea, Romania ; Oradea Municipal Hospital, Romania.
Clujul Med. 2014;87(3):135-42. doi: 10.15386/cjmed-339. Epub 2014 Aug 5.
Along with the remarkable progress registered in oncological treatment that led to increased survival of cancer patients, treatment-related comorbidities have also become an issue for these long-term survivors. Of particular interest is the development of cardiotoxic events, which, even when asymptomatic, not only have a negative impact on the patient`s cardiac prognosis, but also considerably restrict therapeutic opportunities. The pathophysiology of cytostatic-induced cardiotoxicity implies a series of complex and intricate mechanisms, whose understanding enables the development of preventive and therapeutic strategies. Securing cardiac function is an ongoing challenge for the pharmaceutical industry and the physicians who have to deal currently with these adverse reactions. This review focuses on the main mechanism of cardiac toxicity induced by anticancer drugs and especially on the current strategies applied for preventing and minimizing the cardiac side effects.
随着肿瘤治疗取得显著进展，癌症患者的生存率得以提高，与治疗相关的合并症也成为这些长期幸存者面临的一个问题。特别值得关注的是心脏毒性事件的发生，这些事件即使无症状，不仅会对患者的心脏预后产生负面影响，还会极大地限制治疗机会。细胞毒性药物诱导的心脏毒性的病理生理学涉及一系列复杂且错综复杂的机制，了解这些机制有助于制定预防和治疗策略。确保心脏功能对制药行业以及目前必须应对这些不良反应的医生来说，仍然是一项持续的挑战。本综述重点关注抗癌药物诱导的心脏毒性的主要机制，尤其是目前用于预防和尽量减少心脏副作用的策略。
